XUND secures Pre-Series A: 6 million euros to strengthen European leadership in AI-powered healthcare
The investment, led by Lead Ventures and joined by J&T Ventures, strengthens XUND’s role in AI-powered healthcare. XUND will accelerate expansion in DACH and the UK, driven by increasing demand for certified solutions. By advancing MDR-certified solutions and aligning with the EU’s InvestAI initiative, XUND is shaping the future of AI-driven advancements in Europe.
Vienna-based healthtech scale-up XUND, which specializes in building industry-leading Software as a Medical Device (SaMD), has successfully closed a 6 million euro Pre-Series A funding round. The round will help accelerate XUND’s expansion across Europe, with a strategic focus on its core markets in DACH and the UK.
Strengthening XUND’s position in digital health
With new funding and an increasingly comprehensive portfolio of MDR-certified SaMD solutions, XUND is further strengthening its position as a homegrown European champion in digital health technology. With demand for AI-powered medical devices surging across the continent, XUND is well-positioned for rapid growth. Over the coming months, the company will accelerate its expansion in DACH and the UK, leveraging its MDR-certified technology to enable digital interactions from prevention to diagnosis.
Backed by leading investors
The investment round was led by Lead Ventures and joined by J&T Ventures, with continued support from existing investors MassMutual Ventures, tba network, and LANA Ventures, who reaffirmed their commitment to XUND’s mission and growth trajectory. “We are thrilled to partner with XUND, a company that brings clarity to the most important decisions in healthcare. Their commitment to digitizing the patient journey not only enhances patient care but also streamlines operations for healthcare providers. The long-anticipated synthesis of AI technology in patient care is finally happening widely and it is truly exciting to bring down the walls between new technologies and legacy healthcare systems. We have immense confidence in XUND's team and vision, and are eager to support their bold expansion efforts to transform healthcare delivery.” said Balázs Haszonics, Managing Partner at Lead Ventures.
David Polach, Partner at J&T Ventures: “The future of healthcare is not just digital — it’s intelligent, seamless, and deeply integrated. Our investment in XUND is driven by the thesis that AI-powered SaMD solutions will be the foundation of a more efficient, accessible, and data-driven healthcare system. What sets XUND apart is not only its world-class technology and the trust it has earned from some of the biggest names in healthcare but also the strength of its founding team and their bold vision. Their deep expertise, relentless execution, and commitment to transforming digital health give us full confidence that XUND is poised to become a global leader, redefining the future of healthcare at scale.”
Driving AI innovation in European healthcare
At the same time, XUND is consolidating its role as a critical infrastructure provider in Europe's evolving healthcare landscape — fully aligned with the EU's latest InvestAI initiative, which plans to mobilize 200 billion euros for investment in AI solutions that strengthen technological sovereignty. As Europe continues to advance its leadership in AI-driven healthcare, XUND is well-positioned to play a key role in shaping this transformation.
Tamás Petrovics, Co-Founder and CEO of XUND: “The latest investment is a testimony to the hard work of our team over the past years. It will help us accelerate our expansion across Europe while advancing the integration of our medical devices and RAVE, our cutting-edge large language model (LLM) solution. We are laying the foundation for a data-driven, personalized healthcare system that redefines how care is delivered — today and tomorrow.”
Additional information on the investors
About Lead Ventures
Budapest-based Lead Ventures partners with startups that have demonstrated market validation and need capital to scale. With a focus on founders from the CEE region and the Baltics, it invests in high-potential B2B software companies across various industries, providing funding and strategic support to help them expand on international markets. Beyond financial investment, Lead Ventures offers strategic guidance and leverages its collective intelligence and extensive network to help its portfolio companies to scale globally. Its wider team intends to serve as a resource hub for each practice area, peer-to-peer connections and access to prominent later stage investors. For more information, visit www.leadventures.eu.
About J&T Ventures
J&T Ventures is a Prague based VC firm managing over €80 million across three funds, with its third fund launched in December 2024. The firm invests up to €3 million in early and growth-stage technology companies across Central and South-Eastern Europe, focusing on sectors with strong innovation potential. With 30 investments across 7 countries and 5 successful exits, J&T Ventures continues to support promising businesses on their growth journey. For more information, visit https://www.jtventures.cz/en/home.
About MassMutual Ventures
MassMutual Ventures (MMV) is a multistage global venture capital firm investing in financial technology, enterprise SaaS, healthtech, climate technology, and cybersecurity companies. With teams based in London, Singapore, and Boston, MMV manages over $1 billion in investment capital across the globe. We help accelerate the growth of the companies we partner with by providing capital, connections, and advice. With our deep expertise and extensive network, MMV helps entrepreneurs build compelling and scalable companies of value. For more information, visit www.massmutualventures.com.
About tba network
The Tyrolean Business Angel Network is an association of over 30 private investors from South and North Tyrol, dedicated to making a significant contribution to the growing startup ecosystem in the Alpine region. The tba network supports ambitious founders not only with venture capital but also by offering entrepreneurial expertise and valuable connections, thus laying the foundation for future generations of entrepreneurs. For more information, visit https://tba.network/en/.
About LANA Ventures
LANA Ventures GmbH invests in ground breaking life science and health tech ventures that have the potential to dramatically improve patient lives and advance societal development. LANA Ventures is the family office of the PhagoMed founders.
About XUND
Founded in Vienna in 2018, the healthtech scale-up XUND specializes in developing Software as a Medical Device (SaMD), enabling digital interactions from prevention to diagnosis. With the vision of bringing clarity to the most important decisions in healthcare, XUND’s products are already used by leading insurers, hospitals, and pharmaceutical companies as the first digital point of contact. Today, the company employs more than 40 people across its locations in Vienna, Budapest, and London.